ENTX (Entera Bio Ltd.) Gross Profit Margin

Corporate emblem and logo of Entera Bio Ltd. (ENTX)

Patents for the ProNeura platform protect the revenues of Entera Bio Ltd. (ENTX), which is reflected in the gross margin trends. Entera Bio Ltd. (ENTX) is optimizing costs by replacing cold chain protein delivery with oral methods. However, success depends on the recognition of new osteoporosis treatment forms by endocrinologists. The value of 0.00 serves as a current metric helping to assess the risk of overpaying for the asset when the chart reaches extremes.

ENTX (Entera Bio) Gross Margin history from 07/04/2022 to 11/19/2026

Financial and market metric breakdowns for Entera Bio Ltd (ENTX)

- share price and expert price forecast:
- business market valuation indicators:
Fundamental valuation:ENTX - enterabio.com
Manufactured products of Entera Bio

To select high-quality assets, an investor must evaluate a business's ability to generate profit after covering direct production costs. Gross margin measures the portion of revenue remaining after deducting the cost of goods sold, which is critical for Entera Bio Ltd. (ENTX) during its transition to oral drug formulations, as technological complexities directly impact gross margin distribution and the company's overall financial stability.

Main competitors

Gross Profit Margin Haleon PLC (HLN)|Return on Gross Profit KVUE|Gross Profit Margin Verona Pharma Inc. VRNA|Gross Margin MENS|Ligand Pharmaceuticals - Gross Return on Sales|Gross Profitability Amneal AMRX|Gross Sales Margin Perrigo Company PLC|Alvotech Biopharmaceuticals - Gross Margin|Return on Sales by Gross Profit Liquidia Technologies LQDA|Galapagos N.V. (GLPG) - Gross Profitability|anipharmaceuticals.com - Gross Profit Rate|Return on Gross Profit MNKD|AMPH: Gross Profit Rate|Gross Profitability pacira.com (PCRX)|Gross Margin ARS Pharma (SPRY)|Theravance Biopharma - Return on Gross Profit|Gross Profit Ratio AQST (Aquestive Therapeutics)|SCPH: Return on Gross Profit|Gross Profit Margin Tectonic Therapeutic|TNXP: Gross Margin|SXT China (SXTC) - Gross Margin|Gross Profitability eupraxiapharma.com|BioHarvest Sciences (BHST) - Return on Sales by Gross Profit|Gross Profitability Invizyne (EXOZ)|ORMP - Gross Profit Margin|Gross Margin HYFT (MindWalk Holdings, Inc.)|ABVC BioPharma - Gross Profitability|Cumberland Corp - Gross Margin|QNTM - Gross Margin|FibroGen, Inc. (FGEN) - Gross Profitability|TELO: Gross Profit Ratio|RANI (Rani Therapeutics Inc) - Gross Margin|Gross Profit Margin synergychc.com SNYR|Gross Profitability Rallybio Corp. (RLYB)|LEXX - Gross Profit Margin|Gross Margin PULM (pulmatrix.com)|Gross Profit Ratio PTHL (Pheton)|APM - Gross Profitability|Return on Sales by Gross Profit Lyra Therapeutics Inc LYRA|impactbiomedinc.com (IBO) - Gross Profitability|TNF Pharma (TNFA) - Gross Margin|YCBD (cbdmd.com) - Gross Margin|Return on Gross Profit PainReform (PRFX)|Gross Profitability Altamira Therapeutics (CYTO)|Return on Sales by Gross Profit Lipella Pharma|Optinose - Return on Gross Profit|Return on Sales by Gross Profit pieris.com (PIRS)|PROC - Gross Profitability|Gross Profitability Margin PTPI|QLI: Gross Margin|Gross Profit Margin ACELYRIN Inc. (SLRN)|TFFP (TFF Pharmaceuticals, Inc) - Gross Margin